During treatment, Bcl-2+/CD45− CTCs seemed to be a dynamic biomarker for predicting the treatment efficacy and clinical outcome in patients with chemotherapy-naive small cell lung cancer (SCLC) [152]. This evidence concerns the gene BCL2 and small cell lung carcinoma.